Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30566989 | 0.77 | KMT2A (0.45) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL29030632 | 0.77 | KMT2A (0.45) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL11218549 | 0.67 | RAB9A (0.42) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL30465795 | 0.64 | ASIC3 (1.00) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL1039866 | 0.64 | ASIC3 (1.00) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL11590469 | 0.64 | RAB9A (0.38) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL6153238 | 0.64 | ASIC3 (0.50) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL58442 | 0.64 | MEN1 (1.00) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL8249472 | 0.63 | MAOA (0.43) | ASIC3MEN1KMT2ARAB9AADORA2A | |
| SCHEMBL4053052 | 0.63 | MAP2K3 (0.56) | ASIC3MEN1KMT2ARAB9AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010114493-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-10-07 | — | — | WO | claimed |
| US-20120077792-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-03-29 | — | — | US | disclosed |
| WO-2010114493-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-10-07 | — | — | WO | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077792-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | IAPP, RNASE1, LETM1 | ASIC3 1631/4885MEN1 44/4885KMT2A 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.